Core Viewpoint - The company, 3SBio Inc., announced a financing plan through a general mandate by issuing new shares to Pfizer, raising approximately HKD 790 million, netting around HKD 790 million after expenses [1] Group 1: Financing Details - The company issued 31,142,500 shares (approximately 0.3 million shares) at a subscription price of HKD 25.21, representing a discount of about 17.1% compared to the previous trading day's closing price of HKD 30.40 [1] - The shares offered represent about 1.3% of the existing issued share capital and will also account for approximately 1.3% of the enlarged share capital upon completion [1] Group 2: Use of Proceeds - Approximately HKD 630 million of the raised funds will be allocated to enhance the global research and development pipeline for clinical and preclinical projects, as well as to improve production facilities [1] - About HKD 160 million will be used for other general corporate purposes [1] Group 3: Conditions for Completion - The completion of this issuance is subject to the fulfillment of conditions under the subscription agreement or any applicable waivers [1]